» Articles » PMID: 22145575

Hot Spot Analysis for Driving the Development of Hits into Leads in Fragment-based Drug Discovery

Overview
Date 2011 Dec 8
PMID 22145575
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Fragment-based drug design (FBDD) starts with finding fragment-sized compounds that are highly ligand efficient and can serve as a core moiety for developing high-affinity leads. Although the core-bound structure of a protein facilitates the construction of leads, effective design is far from straightforward. We show that protein mapping, a computational method developed to find binding hot spots and implemented as the FTMap server, provides information that complements the fragment screening results and can drive the evolution of core fragments into larger leads with a minimal loss or, in some cases, even a gain in ligand efficiency. The method places small molecular probes, the size of organic solvents, on a dense grid around the protein and identifies the hot spots as consensus clusters formed by clusters of several probes. The hot spots are ranked based on the number of probe clusters, which predicts the binding propensity of the subsites and hence their importance for drug design. Accordingly, with a single exception the main hot spot identified by FTMap binds the core compound found by fragment screening. The most useful information is provided by the neighboring secondary hot spots, indicating the regions where the core can be extended to increase its affinity. To quantify this information, we calculate the density of probes from mapping, which describes the binding propensity at each point, and show that the change in the correlation between a ligand position and the probe density upon extending or repositioning the core moiety predicts the expected change in ligand efficiency.

Citing Articles

Antiviral Agents: Structural Basis of Action and Rational Design.

Menendez-Arias L, Gago F Subcell Biochem. 2024; 105:745-784.

PMID: 39738962 DOI: 10.1007/978-3-031-65187-8_20.


Conservation of Hot Spots and Ligand Binding Sites in Protein Models by AlphaFold2.

Bekar-Cesaretli A, Khan O, Nguyen T, Kozakov D, Joseph-McCarthy D, Vajda S J Chem Inf Model. 2024; 64(3):960-973.

PMID: 38253327 PMC: 10922769. DOI: 10.1021/acs.jcim.3c01761.


Fragment library screening by X-ray crystallography and binding site analysis on thioredoxin glutathione reductase of Schistosoma mansoni.

de Souza Neto L, Montoya B, Brandao-Neto J, Verma A, Bowyer S, Moreira-Filho J Sci Rep. 2024; 14(1):1582.

PMID: 38238498 PMC: 10796382. DOI: 10.1038/s41598-024-52018-2.


Assessing the binding properties of CASP14 targets and models.

Egbert M, Ghani U, Ashizawa R, Kotelnikov S, Nguyen T, Desta I Proteins. 2021; 89(12):1922-1939.

PMID: 34368994 PMC: 8616776. DOI: 10.1002/prot.26209.


Druggable hot spots in trypanothione reductase: novel insights and opportunities for drug discovery revealed by DRUGpy.

Teixeira O, Lacerda P, Froes T, Nonato M, Castilho M J Comput Aided Mol Des. 2021; 35(8):871-882.

PMID: 34181199 DOI: 10.1007/s10822-021-00403-8.


References
1.
Huth J, Park C, Petros A, Kunzer A, Wendt M, Wang X . Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies. Chem Biol Drug Des. 2007; 70(1):1-12. DOI: 10.1111/j.1747-0285.2007.00535.x. View

2.
Hiramatsu H, Kyono K, Higashiyama Y, Fukushima C, Shima H, Sugiyama S . The structure and function of human dipeptidyl peptidase IV, possessing a unique eight-bladed beta-propeller fold. Biochem Biophys Res Commun. 2003; 302(4):849-54. DOI: 10.1016/s0006-291x(03)00258-4. View

3.
Wells J, McClendon C . Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature. 2007; 450(7172):1001-9. DOI: 10.1038/nature06526. View

4.
Liu S, Widom J, Kemp C, Crews C, Clardy J . Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science. 1998; 282(5392):1324-7. DOI: 10.1126/science.282.5392.1324. View

5.
BRANDSEN J, Jones H, MORGAN D, Meijer L, Vesely J, Kim S . Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins. 1995; 22(4):378-91. DOI: 10.1002/prot.340220408. View